Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. develops novel product candidates for brain health disorders as a late-stage clinical biopharmaceutical company trading under MNMD. Its updates focus on a pipeline targeting neurotransmitter pathways, including MM120 Orally Disintegrating Tablet for generalized anxiety disorder and major depressive disorder and MM402 for autism spectrum disorder.
Recurring news includes clinical-program progress, quarterly financial results and business updates, underwritten public offerings, Nasdaq inducement option grants for new employees, and presentations at healthcare and investor conferences.
MindMed presented new studies at ISPOR 24 revealing the significant impact of Generalized Anxiety Disorder (GAD) in the US. The studies showed that GAD diagnosis increases healthcare costs, decreases work productivity, and diminishes health-related quality of life. Undiagnosed GAD patients incur even higher healthcare costs. MindMed is investigating new treatments for GAD and other brain health disorders.
MindMed reported positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), receiving Breakthrough Therapy Designation from the FDA. Cash and cash equivalents were $252.3 million as of March 31, 2024. The Company is on track to initiate its Phase 3 program for MM120 in GAD in the second half of 2024. MindMed completed a $175.0 million offering, delisted from Cboe Canada, and continues trading on Nasdaq under the symbol 'MNMD'. The Company announced favorable results for MM120 and MM402 programs, with detailed plans and updates on clinical trials and FDA meetings.
MindMed presented Phase 2b study data of MM120 for Generalized Anxiety Disorder (GAD) at the APA Annual Meeting in New York. MM120 showed significant efficacy compared to placebo, with rapid and durable improvements in anxiety symptoms sustained for 12 weeks after a single dose. The study demonstrated a 65% clinical response rate and a 48% clinical remission rate. MM120 also improved depressive symptoms and was well-tolerated with mild to moderate adverse events. New epidemiology studies quantified the burden of GAD in the US.
MindMed, a clinical stage biopharmaceutical company, will host a conference call on May 8, 2024, to discuss first quarter financial results. The company is focused on developing novel treatments for brain health disorders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.